4506 Sumitomo Pharma Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4506

TSE Prime

Sumitomo Pharma Co., Ltd.

2,469.5

JPY

+34.0

(+1.40%)

Dec 5, 11:30 am JST

15.92

USD

Dec 4, 9:30 pm EST

Result

ー

PTS

outside of trading hours

2,467.1

Dec 5, 11:29 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	560,035	60,234	82,961	56,413	142.0	28	May 13, 2022	IFRS
Mar, 2023	555,544	-76,979	-47,920	-74,512	-187.6	21	May 15, 2023	IFRS
Mar, 2024	314,558	-354,859	-323,114	-314,969	-792.8	0	May 14, 2024	IFRS
Mar, 2025	398,832	28,804	17,611	23,634	59.5	0	May 13, 2025	IFRS
Mar, 2026 Guidance	429,000	98,000	ー	92,000	231.6	0	Oct 31, 2025	IFRS
YoY	+7.6%	+240.2%	－	+289.3%	+289.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 13, 2020	510,000	24,000	ー	7,000	28	IFRS
-	Jul 30, 2020	495,000	24,000	ー	9,000	28	IFRS
-	Oct 28, 2020	506,000	58,000	ー	42,000	28	IFRS
-	Feb 12, 2021	515,000	49,000	ー	27,000	28	IFRS
-	Apr 23, 2021	516,000	71,200	ー	56,200	28	IFRS
- Results	May 12, 2021	515,952	71,224	77,851	56,219	28	IFRS
Mar, 2022	May 12, 2021	Available in future release
	Jan 31, 2022
	Apr 28, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Oct 31, 2022
	Jan 31, 2023
	Mar 3, 2023
	Apr 28, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Jan 31, 2024
	Apr 30, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024
	Jan 31, 2025
	Apr 28, 2025
Results	May 13, 2025
Mar, 2026	May 13, 2025	355,000	54,000	ー	40,000	0	IFRS
-	Oct 31, 2025	429,000	98,000	ー	92,000	0	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	158,873	+2.2	Available in future release
Mar, 2002	164,117	+3.3
Mar, 2003	172,161	+4.9
Mar, 2004	170,842	-0.8
Mar, 2005	173,899	+1.8
Mar, 2006	245,783	+41.3
Mar, 2007	261,213	+6.3
Mar, 2008	263,992	+1.1
Mar, 2009	264,037	0.0
Mar, 2010	296,261	+12.2
Mar, 2011	379,513	+28.1
Mar, 2012	350,395	-7.7
Mar, 2013	347,724	-0.8
Mar, 2014	387,693	+11.5
Mar, 2015	371,370	-4.2
Mar, 2016	403,206	+8.6
Mar, 2017	411,638	+2.1
Mar, 2018	466,838	+13.4
Mar, 2019	459,267	-1.6
Mar, 2020	482,732	+5.1
Mar, 2021	515,952	+6.9
Mar, 2022	560,035	+8.5
Mar, 2023	555,544	-0.8
Mar, 2024	314,558	-43.4
Mar, 2025	398,832	+26.8
Mar, 2026 Guidance	429,000	+7.6	98,000	+240.2	ー	-100.0	231.6	+289.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	314,558	-354,859	-113	-111.93	-30.85	0.31	-792.8
Mar, 2025	398,832	28,804	7.22	14.52	2.86	0.48	59.5
Mar, 2026 Guidance	429,000	98,000	22.8	34.64	11.82	0.55	231.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	560,035	88,173	84,866	56,413	142.0
Fiscal Year	Mar, 2022	Mar, 2018	Mar, 2018	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	236,255	-48,064	-68,954	-67,229	-169.2	7	May 15, 2023	IFRS
Oct - Mar, 2023	161,916	-268,361	-266,987	-247,228	-622.3	0	May 14, 2024	IFRS
Oct - Mar, 2024	218,083	36,983	50,017	55,863	140.6	0	May 13, 2025	IFRS
Oct - Mar, 2025 Guidance	201,878	1,843	ー	-6,860	-17.3	0	Oct 31, 2025	IFRS
YoY	-7.4%	-95.0%	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	-76,979	64,356	11,937	52,419	-146,817	143,478	12.64	IFRS
Mar, 2024	-354,859	-208,857	-241,893	33,036	77,851	29,047	3.20	IFRS
Mar, 2025	28,804	116,254	16,500	99,754	-108,836	23,116	3.11	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	152,642	-86,498	-56,127	-67,741	-170.5	ー	Oct 31, 2023	IFRS
Apr - Sep, 2024	180,749	-8,179	-32,406	-32,229	-81.1	ー	Oct 30, 2024	IFRS
Apr - Sep, 2025	227,122	96,157	92,802	98,860	248.8	ー	Oct 31, 2025	IFRS
YoY	+25.7%	－	－	－	－

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	82,386	-31,247	-49,064	-49,967	-125.8	-37.9	Jan 31, 2024	IFRS
Jan - Mar, 2024	79,530	-237,114	-217,923	-197,261	-496.5	-298.1	May 14, 2024	IFRS
Apr - Jun, 2024	90,675	-3,105	17,203	15,937	40.1	-3.4	Jul 31, 2024	IFRS
Jul - Sep, 2024	90,074	-5,074	-49,609	-48,166	-121.2	-5.6	Oct 30, 2024	IFRS
Oct - Dec, 2024	112,434	21,405	56,432	53,448	134.5	19.0	Jan 31, 2025	IFRS
Jan - Mar, 2025	105,649	15,578	-6,415	2,415	6.1	14.7	May 13, 2025	IFRS
Apr - Jun, 2025	108,002	20,400	11,932	11,206	28.2	18.9	Jul 31, 2025	IFRS
Jul - Sep, 2025	119,120	75,757	80,870	87,654	220.6	63.6	Oct 31, 2025	IFRS
YoY	+32.2%	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	133,264	+5.4	Available in future release
Jan - Mar, 2021	121,190	-3.6
Apr - Jun, 2021	131,196	-2.0
Jul - Sep, 2021	162,534	+27.3
Oct - Dec, 2021	138,342	+3.8
Jan - Mar, 2022	127,963	+5.6
Apr - Jun, 2022	159,876	+21.9
Jul - Sep, 2022	159,413	-1.9
Oct - Dec, 2022	140,976	+1.9
Jan - Mar, 2023	95,279	-25.5
Apr - Jun, 2023	75,686	-52.7
Jul - Sep, 2023	76,956	-51.7
Oct - Dec, 2023	82,386	-41.6
Jan - Mar, 2024	79,530	-16.5
Apr - Jun, 2024	90,675	+19.8
Jul - Sep, 2024	90,074	+17.0
Oct - Dec, 2024	112,434	+36.5
Jan - Mar, 2025	105,649	+32.8
Apr - Jun, 2025	108,002	+19.1
Jul - Sep, 2025	119,120	+32.2	75,757	－	80,870	－	220.6	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	162,534	75,757	80,870	87,654	220.6
Fiscal Year	Sep, 2021	Sep, 2025	Sep, 2025	Sep, 2025	Sep, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	1,023.80	35.8	1,134,742	406,749	280,999	0.82	May 15, 2023	IFRS
Mar, 2024	392.82	17.2	907,506	156,063	-22,665	2.68	May 14, 2024	IFRS
Mar, 2025	426.59	22.8	742,604	169,479	46,784	1.80	May 13, 2025	IFRS
Apr - Sep, 2025	668.50	34.1	778,404	265,588	147,516	0.99	Oct 31, 2025	IFRS

Sumitomo Pharma Co., Ltd.(4506) Financial Results